ALEXION: Orphan Drugs and Innovative Biologics = Irresistible Combination!

February 2012 | 6 pages | ID: ABCB9F730E3EN
MP Advisors

Abstracts

Alexion (ALXN) should join the club of “$ billion revenues” in 2012 and the growth trajectory continues to look promising. Soliris (L, PNH, aHUS) should grow further from geography and label expansion in other indications targeting rare and high unmet need. Through acquisition, ALXN has diversified beyond soliris and experience in developing and marketing orphan drugs should increase its value beyond Genzyme… For more details, please read our report released on February 15, 2012 on ALXN, titled “Orphan Drugs and Innovative Biologics = Irresistible Combination!”.

Key words: Alexion, Acute Hormonal Rejection , Atypical Hemolytic Uremic Syndrome (aHUS), Dry AMD, Eculizumab, ENB-0040, Label expansion, Myasthenia Gravis, Neuromyeletis Optica, Paroxysmal Nocturnal Hemoglobinuria (PNH), Soliris, STEC-HUS, Hypophosphatasia (HPP), Molybdenum Cofactor Deficiency, TT30

Contents

COMPANIES MENTIONED

ALEXION